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Purpose/Objective: New commercial dosimetry systems need 
careful characterization at several beam energies and beam 
modalities, since many different photon MV beam modalities 
are employed in radiotherapy. Such characterizations can 
furthermore benefit from the comparison with similar, in-
house developed solutions. In this study, basic dosimetric 
response of the commercial Exradin W1 plastic scintillator 
detector (PSD) is investigated and compared with an in-house 
developed PSD system for five different photon MV energies. 
Both systems employ PSDs similar in design, calibrated using 
the same method, but differing primarily in the signal 
detection hardware.  
Materials and Methods: The two investigated PSD systems 
were the commercial Exradin W1 (Standard Imaging Inc.) and 
the in-house developed ME40 system (DTU Nutech). The two 
PSD systems were compared with respect to calibration, field 
size dependence and reference dose. Measurements were 
performed using a Varian TrueBeam linear accelerator for 
three conventional photon energies (6 MV, 10 MV and 15 MV) 
and two flattening filter free (6 MV FFF and 10 MV FFF). Both 
systems were calibrated as outlined in the Exradin W1 
product manual, and the Cerenkov light ratio (CLR) 
calibration coefficients were determined for all five photon 
energies. Absolute dose calibration was performed for 6 MV 
only. Concerning field size dependence, output factors were 
measured for jaw-collimated fields from 2 cm x 2 cm to 40 
cm x 40 cm. An IBA FC65-G Farmer chamber and a PTW 31014 
PinPoint chamber were used as reference for the output 
factor measurements. Reference dose to water was measured 
at 90 cm source-to-surface distance and 10 cm depth for a 10 
cm x 10 cm field size and compared with values obtained 
using the Farmer chamber. 
Results: The CLR coefficients of both systems were found to 
be systematically changing with photon beam quality to a 
maximum difference of 1.1 % (15 MV relative to 6 MV). 
Changes in response due to field size dependence were as 
large as 3.3 % for the W1 and 5.4 % for the ME40, biasing the 
output factor measurements for large fields. The 
discrepancies were generally largest for the highest beam 
qualities (10 MV and 15 MV). Measurements of reference dose 
to water yielded differences up to 1.5 % when compared with 
the Farmer chamber values for all investigated beam 
qualities; the largest differences were again seen for 10 MV 
and 15 MV relative to 6 MV. 
Conclusions: The results show that CLR coefficients should 
be determined for all investigated beam qualities when using 
PSDs for measurements involving more than one photon MV 
energy. The large field output factor measurements suggest 
the potential systematic uncertainties associated with the 
use of PSDs in large fields or under circumstances where the 
fibre irradiation geometry is unfavourable. Differences in 
dose measurements compared with Farmer chamber values 
suggest that the use of PSDs to measure kQ factors for 
ionization chambers should be approached with caution. 
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Purpose/Objective: Uptake of IMRT techniques within the UK 
has been relatively slow compared to some other countries 
(in August 2012 13.6% of radiotherapy patients in England 
received IMRT). Later that year the UK government created a 
Radiotherapy Innovation Fund (RIF), releasing £23M of 
funding to centres to increase IMRT capacity. The aim of the 
fund was to address obstacles to IMRT treatment and reach a 
goal of treating more than 24% of all radical radiotherapy 
patients with IMRT. Prior to the announcement of the fund a 
survey of radiotherapy centres was carried out in 2012 
collecting data on uptake, obstacles to implementation, 
equipment, delivery techniques and verification methods. A 
repeat survey has been carried out in 2014 to assess the 
impact of the RIF and also to identify key changes. 
Materials and Methods: In the summers of 2012 and 2014, an 
online questionnaire was sent to all 65 UK radiotherapy 
institutions. The questionnaire covered the background and 
equipment, treatment planning system, methods of IMRT 
delivery, planning and quality assurance (QA) time, QA 
equipment, sites measurement tolerances, workload, and 
future QA plans.  
Results: 96.9% (63/65) and 86.2% (56/65) responded in 2012 
and 2014, respectively. All centres use 6MV with some use of 
10MV (30%) and a few using 8MV (3%) and 15MV (3%). There 
has been a shift towards more complex treatment planning 
algorithms with an increase in Monte Carlo based algorithms 
and a reduction in pencil beam methods. There has also been 
a significant increase in the use of VMAT (34% to 74%) with a 
slight reduction in fixed field IMRT (41% to 35% for dynamic 
and 49% to 41% for step and shoot).  
In 2012 all centres reported the need to perform physical 
measurements for verification, dropping to 97% in 2014, 
being most common in head and neck (84%) and lung SABR 
(82%). The most commonly used gamma parameters to 
analyse the measurements is 3%/3mm, however for the more 
complex plans (H&N and prostate & pelvic node) there has 
been an increase in the use of 3%/2mm (12% to 20%) and 
2%/2mm (0% to 10%), see table 1. In 2012, 94% of these 
measurements were made by physicists, dropping to 88% in 
2014. There has been an increase in the use of software for 
verification from 63% in 2012 to 95% in 2014, with a 
simultaneous increase of second dose distribution 
calculations from 9% to 26%. In 2014 centres cited that they 
wished to introduce EPID based QA (42%), introduction of 
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more software based verification (48%) and to stopping 
measurements altogether (25%). 
Conclusions: There has been a significant increase in the 
uptake of IMRT techniques within UK centres in recent years, 
possibly aided by the RIF. VMAT delivery has taken over a 
significant proportion of step-and-shoot IMRT and also some 
dynamic fixed gantry IMRT. Whilst the verification workload 
burden is still considerable for physics staff, there has been a 
shift towards software based verification to replace physical 
measurements.  
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Purpose/Objective: Total body irradiation (TBI) is a special 
radiotherapy technique, used before bone marrow 
transplant, aiming to deliver a homogeneous dose to the 
whole body, with an accepted range of dose homogeneity 
within ±10% of the prescribed dose. The moving couch 
technique provides dose uniformity due to the application of 
dynamic TPR. 
The purpose of this study is to assess the reliability of metal–
oxide–semiconductor field-effect transistors(MOSFETs) for in-
vivo verification of the delivered dose and to evaluate the 
patient dose homogeneity for our TBI moving couch 
technique. 
Materials and Methods: Dosimetric data of 16 patients 
treated by TBI with moving couch and 6 MV were 
retrospectively analyzed. 
MOSFET dosimeters were calibrated against a Farmer 
chamber in a Perspex slab phantom and tested in an 
anthropomorphic phantom, under moving couch TBI 
conditions. 
Before treatment, a total body CT scan was acquired with 
the patient in treatment position. CT images were used to 
calculate the mid-line dose at 5 locations in the patient’s 
body (head, neck, mediastinum, umbilicus and thigh), using 
Tissue-Phantom-Ratio (TPR) values according to the 
separation of each location and prescribed dose at mid-line 
of the umbilicus. 
Patient in-vivo dosimetry was performed during first fraction 
for all patients. Patient entrance dose was measured by 
MOSFETs at the same 5 locations, then converted to mid-line 
dose, and compared to calculated values. 
Patient dose homogeneity was assessed by the percent 
difference between mid-line values of doses and mid-line 
dose at the umbilicus, for measured and calculated values.  
Results: The mean percentage dose difference between 
measured and calculated values were: -2% ± 6.1% for head, 
0.2% ± 9.5% for neck, 2.3% ± 8.8% for mediastinum, 1% ± 7% 
for umbilicus, and -2.9% ± 9.3% for thigh. A difference in dose 
of more than 10% was found in 14/16 (87.5%) measurements. 
Fig. 1. Comparison between in-vivo measured dose and 
calculated dose at head, neck, mediastinum, umbilicus and 
thigh. Linear regression curves and correlation coefficients 
are specified. The reference curve shows equal measured and 
calculated doses. 
 
 
Fig. 2.Histogram of the difference between in-vivo measured 
and calculated doses at head, neck, mediastinum, umbilicus 
and thigh. The interval of ± 5% is specified. 
 
Acceptable patient dose homogeneity within ±10% of the 
prescribed dose, as determined by in-vivo measurements, 
was achieved for 11/16 (68.7%) patients at head, 13/16 
(81.2%) patients at neck, 13/16 (81.2%) patients at 
mediastinum, and 13/16 (81.2%) patients at thigh location. 
For 11/16 (68.7%) patients hose homogeneity was acceptable 
over the whole body. 
Table 1. Comparison of patient dose homogeneity (defined by 
the percent difference between midline values of doses and 
midline dose at the umbilicus) between in-vivo measurement 
and calculation.  
 
 
Conclusions: If properly calibrated, MOSFETs are suitable for 
TBI in-vivo dosimetry. 
Moving couch technique for TBI enables acceptable patient 
dose homogeneity. Dose homogeneity can be improved by 
adding tissue compensators for head, neck and legs or by 
speed modulation. 
 
 
 
 
 
